Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Eledon Pharmaceuticals reported its first quarter 2024 financial results, highlighting an oversubscribed $50 million private placement. The company dosed the first participant in a clinical trial at the University of Chicago assessing tegoprubart for islet cell transplant rejection in type 1 diabetes patients. They also shared data from a Phase 1b trial for kidney transplantation and the use of tegoprubart in xenotransplantation. Eledon anticipates significant milestones in 2024 and ended the quarter with $42.9 million in cash.
Eledon Pharmaceuticals, Inc. will present updated data from an ongoing Phase 1b trial of tegoprubart at the American Transplant Congress. The trial focuses on preventing rejection in kidney transplant patients. The company will also sponsor a symposium on solid organ transplantation. Details can be found on the company's website.
Eledon Pharmaceuticals, Inc. announced the dosing of the first participant in a clinical trial at the University of Chicago Medicine using tegoprubart to prevent islet cell transplant rejection in type 1 diabetes patients. They also reported positive results from a Phase 1b trial for kidney transplant rejection prevention. Tegoprubart demonstrated safety and effectiveness in protecting organ function in kidney transplant patients with no cases of graft loss or death. The company plans to present the data at the American Transplant Congress. Eledon is conducting multiple trials to evaluate tegoprubart for preventing organ rejection in kidney transplant recipients, showcasing its potential as a promising treatment option.
Eledon Pharmaceuticals announced an oversubscribed $50 million private placement deal with institutional investors, including BVF Partners LP. The financing involves the sale of common stock and pre-funded warrants at specific prices. The net proceeds will be used for pre-commercial activities and general corporate purposes, including the clinical development of its lead product tegoprubart.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.